Wolfgang EIERMANN
Impact in
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Papers in
-
- Breast Cancer Treatment Studies 77
- Oncology 68
- HER2/EGFR in Cancer Research 32
- Cancer Treatment and Pharmacology 20
- Co-authors
- José Baselga (7 shared papers)Janet M. Wolter (4 shared papers)Dennis J. Slamon (8 shared papers)Mark Daniel Pegram (4 shared papers)Virginia E. Paton (1 shared paper)Steven Shak (1 shared paper)Thomas Henry Fleming (1 shared paper)Brian R Leyland-Jones (1 shared paper)
- Journals
- Annals of Oncology (19 papers)Journal of Clinical Oncology (17 papers)European Journal of Cancer (11 papers)The Lancet (8 papers)Cancer Research (5 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Wolfgang EIERMANN
184 papers receiving 33.1k citations
Wolfgang EIERMANN's Hit Papers
Peers
Comparison fields: 5 of 153
- Cancer Research 13.1k
- Oncology 17.3k
- Radiology, Nuclear Medicine and Imaging 5.6k
- Pulmonary and Respiratory Medicine 4.9k
- Pathology and Forensic Medicine 2.6k
Countries citing papers authored by Wolfgang EIERMANN
This map shows the geographic impact of Wolfgang EIERMANN's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang EIERMANN with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang EIERMANN more than expected).
Fields of papers citing papers by Wolfgang EIERMANN
This network shows the impact of papers produced by Wolfgang EIERMANN. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang EIERMANN. The network helps show where Wolfgang EIERMANN may publish in the future.
Co-authors
The 25 scholars most cited alongside Wolfgang EIERMANN, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 198 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Hit paper breakdown → | 2001 | 9395 |
| 2 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Hit paper breakdown → | 2014 | 3645 |
| 3 | Adjuvant Trastuzumab in HER2-Positive Breast Cancer Hit paper breakdown → | 2011 | 2157 |
| 4 | Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes Hit paper breakdown → | 2012 | 2095 |
| 5 | Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation Hit paper breakdown → | 2018 | 1670 |
| 6 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Hit paper breakdown → | 2010 | 1002 |
| 7 | Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial Hit paper breakdown → | 2013 | 664 |
| 8 | 2010 | 607 | |
| 9 | Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update Hit paper breakdown → | 2006 | 597 |
| 10 | 2001 | 585 | |
| 11 | 2008 | 527 | |
| 12 | 2005 | 411 | |
| 13 | Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Hit paper breakdown → | 2014 | 395 |
| 14 | Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Hit paper breakdown → | 2011 | 390 |
| 15 | 1989 | 388 | |
| 16 | 2011 | 384 | |
| 17 | Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. | 1998 | 368 |
| 18 | 2017 | 342 | |
| 19 | 1996 | 335 | |
| 20 | 2013 | 314 |
About Wolfgang EIERMANN
Wolfgang EIERMANN is a scholar working on Cancer Research, Oncology, Genetics, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 198 papers that have together received 34.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (77 papers), HER2/EGFR in Cancer Research (32 papers), Estrogen and related hormone effects (22 papers), Cancer Treatment and Pharmacology (20 papers), Breast Lesions and Carcinomas (11 papers), Advanced Breast Cancer Therapies (11 papers), Ovarian cancer diagnosis and treatment (9 papers) and MRI in cancer diagnosis (8 papers). The work is most often cited by research in Cancer Research (13.1k citations), Oncology (17.3k citations), Radiology, Nuclear Medicine and Imaging (5.6k citations), Pulmonary and Respiratory Medicine (4.9k citations) and Pathology and Forensic Medicine (2.6k citations). Wolfgang EIERMANN has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include José Baselga, Janet M. Wolter, Dennis J. Slamon, Mark Daniel Pegram, Virginia E. Paton, Steven Shak, Thomas Henry Fleming, Brian R Leyland-Jones, Alex Bajamonde and Larry Norton. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, The Lancet and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.